公司代码：688981 公司简称：中芯国际 中芯国际集成电路制造有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部控制 规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项监督 的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内部控 制评价报告是公司董事会的责任。经理层负责组织领导企业内部控制的日常运行。公司董事会及董事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、 准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提高经 营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供合理 保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根 据内部控制评价结果推测未来内部控制的有效性具有一定 ...

Core Viewpoint - The company, Xiangxin Technology, has announced its profit distribution and capital reserve transfer plan for the fiscal year 2024, which includes a cash dividend and a stock increase plan for shareholders [11][12][13]. Company Overview - Xiangxin Technology specializes in the research and production of automotive hardware molds, automotive parts, new energy metal products, robots, automation equipment, and mechanical arms [2][3]. - The company has established a strong market position with advanced mold manufacturing technology and precision stamping technology, recognized as a national high-tech enterprise and a key backbone mold enterprise in China [4][5]. Financial Performance - In 2024, the company achieved a sales revenue of approximately 6.74 billion yuan, representing a year-on-year increase of 18.25% [5]. - The net profit attributable to shareholders was approximately 359.44 million yuan, a decrease of 11.63% compared to the previous year [5]. - The net cash flow from operating activities was approximately 294.20 million yuan, down 19.92% year-on-year [5]. Profit Distribution Plan - The profit distribution plan includes a cash dividend of 5.35 yuan per 10 shares (including tax) and a capital reserve transfer of 3 shares for every 10 shares held [11][12]. - The total cash dividend payout is estimated at approximately 109.21 million yuan, accounting for 30.38% of the net profit attributable to shareholders [12][13]. Shareholder Meeting - The profit distribution and capital reserve transfer plan will be submitted for approval at the annual shareholder meeting scheduled for May 15, 2025 [10][46].

Core Viewpoint - The company, Shanghai Univey Biotech Co., Ltd., has conducted a self-evaluation of its internal control effectiveness as of December 31, 2024, and found no significant defects in both financial and non-financial reporting internal controls [3][34]. Internal Control Evaluation Conclusion - The board of directors concluded that the company has maintained effective internal controls over financial reporting in all significant aspects [3]. - No significant defects were identified in non-financial reporting internal controls as of the evaluation report date [3]. Internal Control Evaluation Work Situation Evaluation Scope - The evaluation scope was determined based on a risk-oriented principle, covering the company and its important subsidiaries, focusing on five main elements of internal control: internal environment, risk assessment, control activities, information and communication, and internal supervision [4]. Internal Environment - The company has established a governance structure in compliance with relevant laws and regulations, ensuring effective division of responsibilities and checks and balances [5][6]. - Internal audit functions are managed by the corporate management department, which oversees both internal and external audits [8]. Risk Assessment - The company has identified various internal risk factors, including management integrity, employee competence, and operational safety, and has established a risk management framework to address these risks [10][11]. Control Activities - The company has implemented control policies and procedures, including authorization management, segregation of incompatible duties, accounting system controls, asset protection controls, and independent auditing controls [13][14]. Information and Communication Control - A robust information and communication system has been established, ensuring effective information flow across departments and timely financial reporting [15]. Internal Control Defects Recognition and Rectification - The company has not identified any significant or important defects in internal controls during the reporting period [34]. Company Overview Main Business - The company provides life science reagents and related instruments, consumables, and comprehensive technical services, focusing on antibody-based products [38]. - It has integrated over 60 well-known brands and offers more than 9.7 million SKUs, covering various research areas in life sciences [38][41]. Operating Model - The company employs a dual procurement model, including stock procurement and sales-driven procurement, to meet the diverse needs of its clients [42]. - Sales are conducted through a nationwide network of subsidiaries and offices, complemented by an online platform [43][44]. Production Model - The company primarily acts as an agent for third-party brand products while also engaging in self-production through its subsidiaries [48][49]. Research and Development - The company focuses on innovative research and development based on customer needs, with dedicated teams for product and technology development [51][53].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300838 证券简称：浙江力诺 公告编号：2025-012 浙江力诺流体控制科技股份有限公司 一、重要提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以137,978,000股为基数，向全体股东每10股派发现金红 利1.50元（含税），送红股0股（含税），以资本公积金向全体股东每10股转增0股。 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 中汇会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：未变更。 非标准审计意见提示 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务 公司专注于工业控制阀的研发、生产、销售和售后服务，并为 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-008 根据中国证券监督管理委员会发布的《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第2号——创业板上市公司规范运作》及《上市公司监管指引第2号——上市公司募集资 金管理和使用的监管要求》等相关法律、法规和规范性文件规定，恩威医药股份有限公司（以下简 称"公司"或"本公司"）董事会编制了2024年度募集资金存放与实际使用情况的专项报告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行股票注册的批复》（证监许 可[2022]1786号）同意注册，并经深圳证券交易所同意，公司首次向社会公开发行人民币普通股（A 股）股票17,540,000股，每股面值1.00元，发行价格为人民币29.80元/股。本次募集资金总额为人民币 522,692,000.00元，扣除发行费用（不含增值税）人民币79,741,650. ...

Core Viewpoint - The company has ensured the authenticity, accuracy, and completeness of its financial reports and other disclosures, taking legal responsibility for any misleading statements or omissions [2][3][4]. Financial Data - The first quarter financial statements for 2025 are unaudited, with the company confirming that there were no profits from mergers with controlled entities in the current or previous periods [5][6]. - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year [6]. Shareholder Information - The company has reported that there are no changes in the major shareholders or their shareholding status compared to the previous period [4]. Supervisory Board Meeting - The third supervisory board meeting was held on April 18, 2025, with all five supervisors present, and the meeting followed legal and procedural requirements [7]. - The supervisory board approved several key resolutions, including the annual work report, annual report and summary, profit distribution plan, and the special report on the use of raised funds [8][10][13][15]. Financial Reports and Budgets - The supervisory board confirmed that the 2024 annual financial statements accurately reflect the company's financial status and operational results, and the 2025 budget is deemed reasonable [17]. - The board also approved the evaluation report on internal controls, affirming that the company has established a sound internal control system [29]. Related Party Transactions - The supervisory board reviewed and approved the execution of related party transactions for 2024 and the expected transactions for 2025, confirming that they are conducted fairly and do not harm the interests of the company or its shareholders [20][25][26]. Accounting Estimates - The board approved changes in accounting estimates, stating that they provide a more reliable and relevant reflection of the company's financial status [27]. Quarterly Report - The supervisory board reviewed the first quarter report for 2025, confirming that it complies with legal and regulatory requirements and accurately reflects the company's operational and financial conditions [30].

登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证券代码：000728 证券简称：国元证券 公告编号：2025-013 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □ 适用 √ 不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √ 适用 □ 不适用 是否以公积金转增股本 □ 是 √ 否 公司经本次董事会审议通过的利润分配预案为：以现有总股本4,363,777,891股为基数，向全体股东每10 股派发现金红利人民币1.00元（含税），合计派发现金人民币436,377,789.10元（含税），不送红股，不 以公积金转增股本。本预案尚需提交公司2024年度股东大会审议。 董事会决议通过的本报告期优先股利润分配预案 □ 适用 √ 不适用 二、公司基本情况 (一)公司简介 ■ （二）报告期主要业务或产品简介 公司报告期内业绩变化符合行业发展状况，主要业务的经营情况详见 ...

江苏振江新能源装备股份有限公司 江苏振江新能源装备股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日 （内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内 公司代码：603507 公司简称：振江股份 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制 ...

安徽省建筑设计研究总院股份有限公司 2024 年度内部控制自我评价报告 安徽省建筑设计研究总院股份有限公司 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业"内部控制规范体系"），结合安徽省建筑设计研究总院股份 有限公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，对公司截至 2024 年 12 月 31 日（内部控制评价基准日） 的内部控制有效性进行了自我评估。 一、重要声明 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任 何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性 承担个别及连带责任。 建立健全并有效实施内部控制是公司董事会的责任；监事会对董事会建立和 实施内部控制进行监督；经理层负责组织领导企业内部控制的日常运行。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。 此外，由于内、外部情况的变化可能导致内部控制变得不恰当，或对控制政 策和程序遵循 ...

Core Viewpoint - The internal control evaluation report of Jinxi Axle Co., Ltd. indicates that the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial internal controls as of the evaluation date [1][2][5]. Internal Control Evaluation Conclusion - The company confirmed that there are no significant deficiencies in financial reporting internal controls as of the evaluation date [2]. - The company also reported no significant deficiencies in non-financial reporting internal controls [2]. - No factors affecting the effectiveness of internal control evaluations have occurred between the evaluation date and the report issuance date [2]. Internal Control Evaluation Work Situation - The evaluation scope included all major units, businesses, and high-risk areas, with 100% of total assets and operating income included in the evaluation [3]. - The evaluation was based on the enterprise internal control standard system and the company's internal control manual [5]. Internal Control Deficiency Identification and Rectification - The company did not identify any significant deficiencies in financial reporting internal controls during the reporting period [6]. - Minor deficiencies were identified in non-financial reporting areas such as contract management and equipment management, which have been rectified without substantial impact on the internal control system [6]. Other Significant Internal Control Matters - The company has completed all rectifications of deficiencies identified in the previous year [6]. - The internal control system is reported to be operating well, with no significant or important control deficiencies found, ensuring effective internal controls in all major aspects [6].